You're contacting media contact of this press release

Title: Nava Health Redefines Women’s Longevity with Precision Bioidentical Hormone Therapy Following Landmark 2025 Menopause Study

United States, 20th Jan 2026 — Nava Health, a leading integrative and functional medicine provider, is redefining the future of women’s longevity care through precision-driven hormone solutions following insights from a landmark 2025 menopause study. The study highlights the profound long-term health impact of hormonal imbalance during midlife, reinforcing the need for personalized, technology-enabled menopause care—an area where Nava Health continues to lead with innovation.As women’s life expectancy increases, menopause is no longer viewed as a brief transition but as a pivotal phase that can shape metabolic health, cardiovascular resilience, cognitive function, bone density, and overall vitality for decades. Nava Health addresses this challenge through an advanced functional medicine model that integrates comprehensive diagnostics, medical expertise, and continuous monitoring to deliver individualized care plans.Central to this innovation is Nava Health’s expertise in Bioidentical Hormone Replacement Therapy (BHRT). This precision-based approach uses hormones that are structurally identical to those naturally produced by the body, allowing for more accurate hormonal restoration. Unlike conventional hormone therapies, BHRT at Nava Health is guided by in-depth lab testing, data-driven analysis, and physician-led protocols to ensure optimal safety, efficacy, and long-term outcomes.“The findings from the 2025 menopause study validate what we have long observed in clinical practice—menopause management must be personalized, proactive, and rooted in science,” said Zachary Dancel, Chief Operating Officer of Nava Health. “Our precision-based hormone therapies empower women to take control of their health, energy, and longevity, rather than simply managing symptoms....

This press release is issued by King Newswire